Litcius/Paper detail

The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection

Laura van Wijk, Guus W. de Klein, Matthijs A. Kanters, Gijs A. Patijn, Joost M. Klaase

2020European journal of medical research19 citationsDOIOpen Access PDF

Abstract

BACKGROUND: Emerging evidence indicates that an elevated C-reactive protein-to-albumin ratio (CAR) may be associated with a poor prognosis in pancreatic ductal adenocarcinoma (PDAC). Further evidence showing that this ratio has significant prognostic value could contribute to current prediction models and clinical decision-making. METHODS: Data were analysed of consecutive patients who underwent curative pancreatic resection between 2013 and 2018 and were histologically diagnosed with PDAC. We investigated the relation between the ultimate preoperative CAR and overall survival. RESULTS: A total of 163 patients were analysed. Median overall survival was 18 months (IQR 9-36). Multivariate analysis demonstrated that a higher CAR (HR 1.745, P = 0.004), a higher age (HR 1.062, P < 0.001), male sex (HR 1.977, P = 0.001), poor differentiation grade (HR 2.812, P < 0.001), and positive para-aortic lymph node(s) (HR 4.489, P < 0.001) were associated with a lower overall survival. Furthermore, a CAR ≥ 0.2 was associated with decreased overall survival (16 vs. 26 months, P = 0.003). CONCLUSION: We demonstrated that an ultimate preoperative elevated CAR is an independent indicator of decreased overall survival after resection for PDAC. The preoperative CAR may be of additional value to the current prediction models.

Topics & Concepts

MedicineInternal medicinePancreatic cancerGastroenterologyPancreatic ductal adenocarcinomaMultivariate analysisLymph nodeAdenocarcinomaSurvival analysisOncologySurgeryCancerInflammatory Biomarkers in Disease PrognosisPancreatic and Hepatic Oncology ResearchPancreatitis Pathology and Treatment
The ultimate preoperative C-reactive protein-to-albumin ratio is a prognostic factor for survival after pancreatic cancer resection | Litcius